Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.54 |
| ▸ | IKZF3 | Q9UKT9 | 3/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.54 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.52 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.52 |
| ▸ | STAT3 | P40763 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 3/20 | 0.48 |
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | IL1B | P01584 | 1/20 | 0.48 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17724238 | 1.00 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724108 | 1.00 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724219 | 0.91 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724221 | 0.91 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724220 | 0.91 | CRBN (0.54) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724086 | 0.90 | TNF (0.61) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL19532843 | 0.90 | CRBN (0.52) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724204 | 0.90 | CRBN (0.52) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724223 | 0.90 | TNF (0.61) | CRBNIKZF3DDB1IKZF1CSNK1A1 | |
| SCHEMBL17724142 | 0.90 | CRBN (0.52) | CRBNIKZF3DDB1IKZF1CSNK1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3643709-B1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS LTD (CN) | 2021-10-20 | — | — | EP | disclosed |
| EP-3643709-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2020-04-29 | — | — | EP | disclosed |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2018-07-10 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | KANGPU BIOPHARMACEUTICALS, LTD. (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3214081-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | Kangpu Biopharmaceuticals, Ltd. (CN) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016065980-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | 康朴生物医药技术（上海）有限公司 | 2016-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10017492-B2 | Isoindoline derivative, intermediate, preparation method, pharmaceutical composition and use thereof | IL2, IL1B, IL5 | CRBN 3765/4885IKZF3 208/4885DDB1 3019/4885 |
| US-20170313676-A1 | ISOINDOLINE DERIVATIVE, INTERMEDIATE, PREPARATION METHOD, PHARMACEUTICAL COMPOSITION AND USE THEREOF | IL2, IL1B, IL5 | CRBN 3765/4885IKZF3 208/4885DDB1 3019/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.